Results 261 to 270 of about 12,874,292 (410)

Alcohol-associated liver disease is associated with less adverse outcomes compared to nonalcohol-associated liver disease in patients with COVID-19. [PDF]

Alcohol Clin Exp Res (Hoboken)
Musto JA, Piasecki TM, Smith J, Slutske WS, Fiore MC, Lucey MR.   +5 more
europepmc   +1 more source

Expert consensus on research paradigms and technological layout for clinical priority diseases in traditional Chinese medicine: Rheumatoid arthritis

Advanced Chinese Medicine, EarlyView.
Abstract Rheumatoid arthritis (RA) is a chronic, highly disabling autoimmune disease. Although modern medical treatments have made progress, challenges such as suboptimal efficacy, relapse, difficulties in comorbidity management, and side effects persist.
Dier Jin, Jinping Wang, Zihan Wang, Mei Mo, Xiaojing Liu, Nan Zhang, Xiaoxiao Zhang, Qingwen Tao, Yuan Xu   +8 more
wiley   +1 more source

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis

Hepatology, 2017
P. Dulai, Siddharth Singh, J. Patel, Meera Soni, L. Prokop, Z. Younossi, G. Sebastiani, M. Ekstedt, H. Hagstrom, P. Nasr, P. Stål, V. Wong, S. Kechagias, R. Hultcrantz, R. Loomba   +14 more
semanticscholar   +1 more source

From steatosis to cirrhosis: the role of obesity in the progression of liver disease. [PDF]

J Diabetes Metab Disord
Nowak K, Paluch M, Cudzik M, Syska K, Gawlikowska W, Janczura J.   +5 more
europepmc   +1 more source

Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia, Stephane Rodriguez, Emilie Dugast, Christine Lebrun‐Frenay, Eric Thouvenot, Jérôme de Sèze, Emmanuelle Le Page, Sandra Vukusic, Inès Doghri, Eric Berger, Olivier Casez, Pierre Labauge, Aurélie Ruet, Catarina Raposo, Fabienne Le Frère, Arnaud B. Nicot, Sandrine Wiertlewski, Pierre‐Antoine Gourraud, Laure Michel, Laureline Berthelot, David‐Axel Laplaud   +20 more
wiley   +1 more source

Non-alcoholic fatty liver disease - A global public health perspective.

Journal of Hepatology, 2019
Z. Younossi
semanticscholar   +1 more source

Immunotherapy of Liver Diseases

Journal of Immunology Research, 2019
Dechun Feng, YinYing Lu, Xiaoni Kong, Feng Li   +3 more
openaire   +3 more sources

The pathophysiological role of portal hypertension in metabolic dysfunction-associated steatotic liver disease. [PDF]

Hepatol Commun
Møller S, Sjöstedt SMS, Hobolth L, Mortensen C, Mortensen C, Kimer N.   +5 more
europepmc   +1 more source

CYSTIC DISEASE OF THE LIVER IN A FŒTUS. [PDF]

J.C.B. Smallman
openalex   +1 more source

Multimodal Autonomic Biomarkers Predict Phenoconversion in Pure Autonomic Failure

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Pure autonomic failure (PAF) presents with autonomic failure without other neurological features. A third develop central neurological features, fulfilling criteria for multiple system atrophy (MSA) and Lewy body diseases (LBD), including Parkinson's disease and Dementia with Lewy bodies.
S. Koay, E. Vichayanrat, F. Bremner, F. Valerio, R. Mackenzie, G. Chiaro, G. Ingle, P. McNamara, L. Watson, J. N. Panicker, M. P. Lunn, C. Mathias, V. Iodice   +12 more
wiley   +1 more source